The US Food and Drug Administration (FDA) has approved BeiGene’s Tevimbra (tislelizumab-jsgr) along with platinum-containing ...

BeiGene (ONC) has received FDA approval for Tevimbra for first-line esophageal cancer with chemo. Read more here.

We recently published an article titled Why These 15 Biotech Stocks Are Skyrocketing So Far In 2025. In this article, we are ...

The approval for the first-line treatment of esophageal squamous cell carcinoma comes shortly after a label expansion for the ...

BeiGene's Tevimbra wins FDA approval for first-line metastatic ESCC treatment, showing significant survival benefits in PD-L1 ...

BeiGene (ONC) announced the U.S. FDA has approved Ttevimbra in combination with platinum-containing chemotherapy, for the first-line treatment ...

New indication for Tevimbra in combination with platinum-containing chemotherapy as a first-line treatment addresses an unmet ...

BeiGene’s Tevimbra (tislelizumab-jsgr) has been approved by the US Food and Drug Administration (FDA) as part of a first-line ...

J.P. Morgan analyst Jessica Fye maintained a Buy rating on BeiGene (ONC – Research Report) on February 28 and set a price target of $311.00.

The US Food and Drug Administration (FDA) has approved Tevimbra (tislelizumab-jsgr), in combination with platinum-containing ...

Bank of America upgraded shares of Beigene (NASDAQ:ONC – Free Report) from a neutral rating to a buy rating in a report published on Monday morning, MarketBeat.com reports. The brokerage currently has ...

Beigene, Ltd. (NASDAQ:ONC – Get Free Report)’s stock price gapped down prior to trading on Monday following insider selling activity. The stock had previously closed at $271.80, but opened at $255.83.